Evidence map›Paper›PMID 41684322›Full record

ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2026

Cross-sectional study on protective antibodies against influenza A virus subtypes and cross-protection against influenza A(H3N2) subclade K, Portugal, August 2025.

Raquel Guiomar, Camila Henriques, Susana Pereira da Silva, Licínia Gomes, Daniela Dias, Nuno Verdasca, Portuguese Laboratory Network for the Diagnosis of Influenza and Respiratory Viruses, Baltazar Nunes, Ana Paula Rodrigues

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Raquel GuiomarNational Reference Laboratory for Influenza and Other Respiratory Viruses, Infectious Diseases Department, National Institute of Health Dr. Ricardo Jorge, Lisbon, Portugal.
Camila HenriquesNational Reference Laboratory for Influenza and Other Respiratory Viruses, Infectious Diseases Department, National Institute of Health Dr. Ricardo Jorge, Lisbon, Portugal.
Susana Pereira da SilvaDepartment of Epidemiology, National Institute of Health Dr. Ricardo Jorge, Lisbon, Portugal.
Licínia GomesNational Reference Laboratory for Influenza and Other Respiratory Viruses, Infectious Diseases Department, National Institute of Health Dr. Ricardo Jorge, Lisbon, Portugal.
Daniela DiasNational Reference Laboratory for Influenza and Other Respiratory Viruses, Infectious Diseases Department, National Institute of Health Dr. Ricardo Jorge, Lisbon, Portugal.
Nuno VerdascaNational Reference Laboratory for Influenza and Other Respiratory Viruses, Infectious Diseases Department, National Institute of Health Dr. Ricardo Jorge, Lisbon, Portugal.
Portuguese Laboratory Network for the Diagnosis of Influenza and Respiratory VirusesThe members of the Portuguese Laboratory Network for the Diagnosis of Influenza and Respiratory Viruses are listed under Collaborators and at the end of the article.
Baltazar NunesNational School of Public Health, NOVA University, Lisbon, Portugal.
Ana Paula RodriguesDepartment of Epidemiology, National Institute of Health Dr. Ricardo Jorge, Lisbon, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 2025/26 season was marked by co-circulation of influenza A subtypes, with the first detection of A(H3N2) subclade K in September 2025. In August 2025 in Portugal, 14.8% (95% CI: 12.2-17.8) of 886 persons tested had cross-protective antibodies against this subclade. The overall seroprevalence against circulating A(H1N1)pdm09 strains was 28.1% (95% CI: 24.4-32.0). These data highlight the presence of previous cross-reactive antibodies and the possible advantage of vaccination in the extent of detectable antibodies against influenza viruses.

Indexed as

Antibodies, ViralCross ProtectionInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza, HumanInfluenza VaccinesAdolescentAdultAgedChildChild, PreschoolCross ReactionsCross-Sectional StudiesFemaleHumansInfantAntibodies, ViralInfluenza VaccinesA(H3N2) subclade Kantibodiescross-protectionInfluenzaseroprevalence

Identifiers

PMID41684322
PMCPMC12905529

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.